Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Cash (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Change in Cash for 5 consecutive years, with -$37.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 22.12% year-over-year to -$37.7 million, compared with a TTM value of -$570.9 million through Sep 2025, down 242.13%, and an annual FY2024 reading of -$11.5 million, up 91.9% over the prior year.
  • Change in Cash was -$37.7 million for Q3 2025 at Autolus Therapeutics, down from $28.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $519.2 million in Q1 2024 and bottomed at -$429.7 million in Q4 2024.
  • Average Change in Cash over 4 years is -$6.3 million, with a median of -$38.6 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 1417.59% in 2024, while the deepest fall reached 2502.23% in 2024.
  • Year by year, Change in Cash stood at $219.4 million in 2022, then plummeted by 107.53% to -$16.5 million in 2023, then crashed by 2502.23% to -$429.7 million in 2024, then skyrocketed by 91.22% to -$37.7 million in 2025.
  • Business Quant data shows Change in Cash for AUTL at -$37.7 million in Q3 2025, $28.1 million in Q2 2025, and -$131.6 million in Q1 2025.